Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study
10.3760/cma.j.cn501113-20210329-00148
- VernacularTitle:卡瑞利珠单克隆抗体联合阿帕替尼二线治疗不可切除肝细胞癌的临床疗效及安全性分析：一项多中心回顾性研究
- Author:
Guosheng YUAN
1
;
Weimeng HE
;
Xiaoyun HU
;
Qi LI
;
Mengya ZANG
;
Xiao CHENG
;
Wei HUANG
;
Jian RUAN
;
Junjie WANG
;
Jinlin HOU
;
Jinzhang CHEN
Author Information
1. 南方医科大学南方医院感染内科，广州 510515
- Keywords:
Hepatocellular carcinoma;
Safety;
Efficacy;
Camrelizumab;
Apatinib
- From:
Chinese Journal of Hepatology
2021;29(4):326-331
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical efficacy and safety of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma (HCC).Methods:Ninety-four cases with mid-and advanced-stage HCC who received camrelizumab combined with apatinib as second-line treatment were enrolled. Routine blood test, blood biochemical indexes, tumor stage, tumor imaging characteristics, previous treatment strategies and other clinical data before treatment were documented. Imaging examination follow-up results and adverse reactions during treatment were followed up until the end of follow-up or loss of follow-up or death. Kaplan-Meier method was used to analyze the clinical efficacy.Results:As of the last follow-up, 94 cases with mid-and advanced-stage HCC had received camrelizumab combined with apatinib as second-line treatment. Among them, 15 cases were lost to follow-up, 31 cases died, and 48 cases survived. The overall remission rate was 31.9%. The overall disease control rate was 71.3%. The median time to disease-free progression was 6.6 months. The median time to disease progression was not yet available. The 1-year cumulative survival rate was 62.3%. Grade 3 and above adverse reactions mainly included were thrombocytopenia (7.4%), abdominal pain (4.3%), active hepatitis (4.3%), leukopenia (4.3%), diarrhea (3.2%), hand-foot syndrome (3.2%). All adverse reactions were effectively controlled.Conclusion:Camrelizumab combined with apatinib can effectively prolong the survival period of patients with mid-and advanced-stage HCC, and it is well tolerated.
